**Supplemental TABLE 3.** Serious adverse events and adverse events leading to discontinuation from the treatment period, study 1030 (N=281)

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Serious AE** | **AE leading to Discontinuation**\* | **Event details†** |
| Patients with any event, n (%) | 18 (6.4) | 25 (8.9) |  |
| Abscess | 1 |  | 13 yo female, 25 mg/d; this event had a start date during the lead-in study (35 mg/d) and was ongoing when the patient entered the extension study  |
| AggressionAgitationSuicide threat | 1 | 1 | 16 yo male, 25 mg/d; on study day 125, the patient attempted suicide by taking oxycodone hydrochloride, became agitated and violent/aggressive with his mother; he was seen at the ER, but was not admitted; he was discontinued due to a suicide threat, last dose was day 124; the patient refused to return for subsequent study visits  |
| Suicidal behavior AggressionMania | 1 |  | 12 yo male, 50 mg/d; all 3 serious AEs were reported post-therapy: the patient completed the therapy period on study day 183, suicidal behavior was reported on day 200 and was hospitalized that day, discharged on day 212. Aggression was reported on day 233 and the patient was again hospitalized; mania was reported on day 236 while the patient was still in the hospital  |
| Aggression | 1 |  | 15 yo male, 35 mg/d; patient discontinued (no longer willing to participate), taking his last dose on study day 98; his mother reported he was hospitalized day 142 (after discontinuation) after he displayed aggressive behavior and tried to harm his brother; discharged day 156  |
| Initial insomniaAgitationPyromania Hallucination [auditory] | 1 | 1 | 9 yo male, 20 mg/d; dose was decreased from 35 mg/d to 25 mg/d beginning day 28 due to middle insomnia and initial insomnia and decreased to 20 mg on day 60 due to agitation and pyromania; initial insomnia recurred study day 44; the patient experienced agitation, pyromania, and auditory hallucination on day 58; the patient reported he had been hearing voices for the past 3 years; he was taken to the ER and admitted, and discontinued due to the events on day 63, and discharged on day 76. Last treatment-phase dose was day 62 and last taper dose was day 66,  |
| Anger | 1 | 1 | 13 yo male, 50 mg/d; patient was seen in the ER on study day 62 following an argument with his mother; admitted to the psychiatric unit for anger management issues; the patient was discontinued, last dose was day 58; the patient refused to take study drug beginning day 59 and was discharged on study day 71  |
| Bronchial hyper-reactivity | 1 |  | 12 yo male, 35 mg/d; patient went to ER study day 141 and was hospitalized, discharged day 145 and study medication resumed day 146  |
| Femur fracture | 1 |  | 16 yo male, 50 mg/d; the patient suffered a fracture when struck by a car while skateboarding on study day 75  |
| Fetal death | 1 |  | 17 yo female, 50 mg/d; patient completed the treatment phase on study day 182; discontinued subsequent post-therapy treatment (venlafaxine extended release 75 mg/d, started day 211 for major depressive disorder) on study day 237 after learning she was pregnant; last menstrual period was on study day 175, and the estimated date of conception was on study day 219, during the follow-up phase; ultrasonography on day 296 revealed intrauterine fetal demise; details provided in text  |
| Generalized tonic-clonic seizure | 1 |  | 14 yo male, 50 mg/d; patient had a 1-2 min seizure at the study site on study day 106, patient recovered and dose was decreased to 35 mg/d  |
| Ketoacidosis | 1 |  | 14 yo male, 25 mg/d; hospitalized for diabetes and ketoacidosis on study day 15, discharged on study day 18, and resumed study medication on day 21 at a dose of 35 mg/d  |
| Major depression | 1 | 1 | 14 yo female, 35 mg/d; experienced major depression with psychotic features study day 156; patient complained of hearing voices and had over the past few years; she was hospitalized day 156 and discharged day163 after recovery from the event; her last dose was on study day 158  |
| Suicide attemptSuicidal ideation | 1 | 1 | 14 yo female, 50 mg/d; the patient was discontinued study day 28 due to suicidal ideation; a suicide attempt was also reported retrospectively; patient was admitted on study day 29 due to suicidal ideation; details provided in text  |
| Suicide attemptSuicide attempt | 1 | 1 | 15 yo female, 20 mg/d; the patient was discontinued after aborted attempts on study days 67 and 70, respectively; both attempts were not reported until study day 71; her last dose of study drug was on this day; detail in the text  |
| Suicide attempt | 1 |  | 14 yo female, 35 mg/d; patient completed treatment phase on study day 182; she endorsed “active suicidal ideation with any methods (not plan) without intent to act” on the C-SSRS on day 126; an aborted attempt on study day 191 was reported 1 week afterward; the patient was not discontinued; details provided in text  |
| Suicidal ideation Suicide attempt | 1 | 1 | 10 yo female, 50 mg/d; experienced suicidal ideation and suicide attempt on day 154; last dose on this day; patient was hospitalized on study day 155 and discharged on day 156; details provided in text  |
| Suicidal ideation | 1 | 1 | 13 yo female, 50 mg/d; discontinued due to suicidal ideation on study day 50 and sent by the investigator to the ER for hospital admission on day 51  |
| Suicidal ideation | 1 | 1 | 13 yo female, 50 mg/d; hospitalized for suicidal ideation study day 28 after a fight with her boyfriend the previous day; patient was discontinued day 27 due to the event; she was considered recovered and discharged day 40  |
| Suicidal ideation | 1 |  | 17 yo male, 50 mg/d; patient taken to the ER for suicidal ideation on study day 136, hospitalized days 137-138, and restarted study medication day 139; no suicidal behavior for the study duration  |
| Abdominal discomfort |  | 1 | 11 yo female, 25 mg/d; discontinued study day 82  |
| Accidental overdose |  | 1 | 14 yo male, 50 mg/d; accidental overdose of study medication on 9 days, discontinued study day 154  |
| Alcohol poisoning |  | 1 | 17 yo female, 50 mg/d; discontinued study day 29, last dose was day 28  |
| Anger |  | 1 | 12 yo male, 50 mg/d; discontinued study day 97  |
| Anger |  | 1 | 8 yo male, 50 mg/d; discontinued study day 182, last dose was day 166  |
| Blood bilirubin increased |  | 1 | 10 yo female, 25 mg/d; discontinued study day 12  |
| Dermatitis allergic |  | 1 | 16 yo female, 35 mg/d; discontinued study day 11  |
| Headache |  | 1 | 17 yo female, 25 mg/d; discontinued study day 29  |
| Insomnia |  | 1 | 8 yo male, 50 mg/d; discontinued study day 79  |
| Irritability |  | 1 | 12 yo female, 50 mg/d; discontinued study day 42  |
| Irritability |  | 1 | 7 yo female, 35 mg/d; discontinued study day 21  |
| Irritability |  | 1 | 11 yo male, 25 mg/d; discontinued study day 10, last dose on day 8  |
| Mood altered |  | 1 | 15 yo male, 25 mg/d; discontinued study day 8 due to event on day 4  |
| Nausea |  | 1 | 11 yo male, 35 mg/d; discontinued study day 137, last dose on day 112  |
| Pharyngitis |  | 1 | 15 yo female, 35 mg/d; discontinued study day 60  |
| Psychomotor hyperactivity |  | 1 | 10 yo male, 35 mg/d; discontinued study day 14  |
| Psychomotor hyperactivity |  | 1 | 7 yo male, 25 mg/d; discontinued study day 27  |

ER, emergency room; yo, year old.

\*Sites were instructed that if the reason for withdrawal included two or more adverse events, the most serious adverse event was considered the primary reason for withdrawal.

†The dose listed is desvenlafaxine dose at the time of the event, or the last desvenlafaxine dose taken prior to the event for events that occurred post-therapy; day of last dose is reported where it differed from day of discontinuation.